Ongoing Research with Bispecific T Cell Engager Antibodies
Creative Biolabs, T Cell Engager Antibodies,
“Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for the use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells' cytotoxic activity, against cancer cells.” –from wiki
Actually BiTE is a fusion protein that is make up of two single-chain variable fragments (scFvs) of different antibodies, or amino acid sequences from four different genes, on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells, and the other to a tumor cell, which bring the T cell and cancer cell together and thus showed great potentials in cancer therapy.
In terms of their bispecificity, BiTE differs from conventional monoclonal antibodies. Currently it is a type of immunotherapy being explored for use in fighting cancer by helping to engage the body's immune system to detect and target malignant cells. With times, the modified antibodies are designed to engage two different targets simultaneously—T cells to cancer cells. It helps to place the T cells within reach of the targeted cell, with the intent of allowing it to inject toxins and trigger the cell to be involved in apoptosis. With this technology, it is currently being investigated for their potential to treat a wide variety of cancers in clinical trials as well as further researches.
Scientists from Creative Biolabs have successfully constructed and engineered over 10 BiTE antibodies. Moreover, at Creative Biolabs, it can be customized to meet various research needs. For more information on BiTE antibodies, visit http://www.creative-biolabs.com/Bispecific-T-cell-engager-BiTE-Antibodies.html.
, T Cell Engager Antibodies